Market Cap
$46.1B
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
$39.58 ▲ +0.69%
Prev close $39.31Market cap$46.1B
ConsensusStrong Buy
12-mo target$46.29 (+16.9%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)34 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on TEVA right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$17.1B
Inst. Activity
34 buys / 16 sells
Insider Activity
$0.00 buy / $37.8M sell
Insider Net $
-$37.8M
Social Sentiment
43° Neutral
SEC Reports
20
Press Releases
7
Price chart 30d +5.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 fda
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva P
Sep 25, 2026 Event
DEGEVMA
Original Approval — Type 5 - New Formulation or New Manufacturer — INJECTABLE
Sep 18, 2026 Insider
Savage Brian sold 4,503 shares
Interim Chief Legal Officer @ $38.69 ($174.2K)
Sep 18, 2026 Insider
Savage Brian sold 2,525 shares
Interim Chief Legal Officer @ $39.15 ($98.8K)
Sep 18, 2026 Insider
Sep 10, 2026 Press Savage Brian sold 314 shares
Interim Chief Legal Officer @ $38.70 ($12.2K)
Teva priced a ~$4.9B multi-tranche senior notes offering across five maturities (2032-2037), with proceeds to fund the c
Impact 5/10
Teva is launching a multi-tranche debt offering of EUR and USD senior notes across five maturities (2032-2037), with pro
424B5 — Impact 5/10
Sep 4, 2026 Event
Edgar et al v. Teva Pharmaceuticals Industries, Ltd. et al
Court ruling (ksd) — Docket: 2:22-cv-02501
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 7 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | TD Cowen | INITIATE | Buy | 56% |
| Sep 23, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Sep 9, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Sep 4, 2026 | UBS | MAINTAIN | Buy | 55% |
| Aug 12, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jul 28, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| May 6, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Apr 30, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Apr 30, 2026 | UBS | MAINTAIN | Buy | 55% |
| Apr 30, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Price targets
Where 7 covering analysts think TEVA trades over the next 12 months.
$46.29 +16.9% upside Buy
Current$39.58 Low$40.00 Median$47.00 High$55.00 7 analysts
$40.00$55.00
Analyst rating Buy· 1.6/5 as of Oct 2, 2026
Social media sentiment mood -28.6%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 5 bullish, 1 bearish, 2 mixed, 12 neutral · avg impact 3.9/10.Plus 7 press releases.
NEUTRAL424B55/10
Teva is launching a multi-tranche debt offering of EUR and USD senior notes across five maturities (
Sep 9, 2026
NEUTRALCOURT-RULING1/10
The court denied a pro se plaintiff's appeal of a magistrate judge's order requiring her to appear i
Sep 3, 2026
NEUTRALCOURT-RULING2/10
A federal magistrate judge in Kansas granted in part and denied in part a motion to compel non-party
Aug 27, 2026
NEUTRALCLUSTER2/10
Two Teva insiders — a director and an EVP — sold a combined $696K in open-market sales over a one-we
Aug 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
fda
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA
Oct 2, 2026
fda
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA
Oct 1, 2026
Clinical Trial
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
Phase Phase 3 — COMPLETED
Oct 1, 2026
Clinical Trial
Ketoprofen Topical Patch, 20% in the Treatment of Pain Associated With Osteoarthritis Flare of the Knee
Phase Phase 3 — COMPLETED
Oct 1, 2026
short_volume
Short Volume: TEVA — 75.6% short (2.3M / 3.0M)
Short: 2,298,812 | Exempt: 14,394 | TRF Vol: 3,039,201 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.72 | $0.60–$0.89 | — | — | — | $4.2B | 5 |
| Next Q | $0.79 | $0.72–$0.97 | — | — | — | $4.2B | 5 |
| Current FY | $2.17 | $1.91–$2.94 | — | — | — | $16.7B | 8 |
| Next FY | $3.08 | $2.86–$3.35 | 42.2% | — | — | $17.3B | 8 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.716 | — |
| 7d ago | $0.685 | +0.031 |
| 30d ago | $0.000 | +0.716 |
| 60d ago | $0.000 | +0.716 |
| 90d ago | $0.000 | +0.716 |
Institutional ownership
Which big funds own TEVA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $17.1B total value (506,203,497 shares) as of 2026-Q2. Top holders: BlackRock,, Phoenix, WCM. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 63,894,301 | $2.2B | 12.6% | — |
| Phoenix Financial Ltd. | 42,933,367 | $1.5B | 8.5% | — |
| WCM INVESTMENT MANAGEMENT, LLC | 41,315,232 | $1.4B | 8.0% | — |
| MENORA MIVTACHIM HOLDINGS LTD. | 39,854,383 | $1.4B | 7.9% | — |
| Migdal Insurance & Financial Holdings Ltd. | 38,922,212 | $1.3B | 7.7% | — |
| NORGES BANK | 32,299,753 | $1.1B | 6.4% | NEW |
| FMR LLC | 30,258,016 | $1.0B | 6.0% | — |
| STATE STREET CORP | 18,936,548 | $641.6M | 3.7% | — |
| Rubric Capital Management LP | 15,575,000 | $527.7M | 3.1% | — |
| Capital World Investors | 12,536,035 | $424.7M | 2.5% | ADD +41.9% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 32,299,753 | — | $1.1B |
| Capital World Investors | ADD | 8,833,566 | 12,536,035 | +41.9% | $424.7M |
| MEITAV INVESTMENT HOUSE LTD | NEW | — | 9,947,045 | — | $336.9M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | DOUBLED | 1,425,667 | 6,593,221 | +362.5% | $223.4M |
| GOLDMAN SACHS GROUP INC | ADD | 4,826,245 | 6,129,240 | +27.0% | $207.7M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | DOUBLED | 57,244 | 3,832,465 | +6595.0% | $129.8M |
| MILLENNIUM MANAGEMENT LLC | ADD | 1,893,845 | 3,265,321 | +72.4% | $110.6M |
| Assenagon Asset Management S.A. | DOUBLED | 1,339,702 | 3,056,017 | +128.1% | $103.5M |
| CITIGROUP INC | DOUBLED | 832,323 | 2,527,031 | +203.6% | $85.6M |
| AustralianSuper Pty Ltd | TRIM | 3,556,389 | 2,502,805 | -29.6% | $84.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
20 insiders, 50 transactions. Net -$37.8M — $0.00 bought, $37.8M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | SELL | 4,503 | $38.69 | $174.2K |
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | SELL | 2,525 | $39.15 | $98.8K |
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | SELL | 314 | $38.70 | $12.2K |
| Sep 18, 2026 | Savage Brian | Interim Chief Legal Officer | EXERCISE | 4,503 | $34.70 | $156.3K |
| Sep 18, 2026 | MIGNONE ROBERTO | Director | SELL | 367,600 | $39.06 | $14.4M |
| Aug 21, 2026 | Satchi-Fainaro Ronit | Director | SELL | 415 | $37.25 | $15.5K |
| Aug 21, 2026 | Weiss Amir | Chief Accounting Officer | SELL | 6,945 | $37.61 | $261.2K |
| Aug 21, 2026 | Weiss Amir | Chief Accounting Officer | EXERCISE | 2,500 | $19.61 | $49.0K |
| Aug 21, 2026 | Weiss Amir | Chief Accounting Officer | SELL | 2,500 | $37.63 | $94.1K |
| Aug 17, 2026 | Lippman Evan | EVP, Business Development | SELL | 18,600 | $36.57 | $680.3K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TEVA.
Shares short
31,478,314
Settlement Sep 15, 2026
Change vs prior
+11467.5%
Semi-monthly cycle
Days to cover
27.4
At avg daily volume
Of shares outstanding
≈2.7%
Estimate — not % of float
All TEVA filing & press-release reports (31)
- PRESS-RELEASE reportSep 10, 2026
- 424B5 reportSep 9, 2026
- COURT-RULING reportSep 3, 2026
- PRESS-RELEASE reportAug 28, 2026
- COURT-RULING reportAug 27, 2026
- CLUSTER reportAug 26, 2026
- CLUSTER reportAug 10, 2026
- CLUSTER reportAug 6, 2026
- COURT-RULING reportAug 1, 2026
- 8-K reportJul 29, 2026
- COURT-RULING reportJul 24, 2026
- INST-CLUSTER reportJul 20, 2026
- COURT-RULING reportJul 16, 2026
- COURT-RULING reportJul 14, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 3, 2026
- CLUSTER reportJun 16, 2026
- PRESS-RELEASE reportJun 10, 2026
- CLUSTER reportJun 8, 2026
- PRESS-RELEASE reportJun 5, 2026
- CLUSTER reportMay 18, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 29, 2026
- COURT-RULING reportApr 16, 2026
- PRESS-RELEASE reportMar 19, 2026
- CLUSTER reportMar 9, 2026
- CLUSTER reportMar 9, 2026
- CLUSTER reportMar 9, 2026
- CLUSTER reportMar 9, 2026
- INST-CLUSTER reportFeb 28, 2026